Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients

H. Gradman, Alan; E. Schmieder, Roland; Lins, R.; Nussberger, Juerg; Chiang, YannTong; P. Bedigian, Martin

doi:10.1161/01.cir.0000156466.02908.ed

Public

Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients

Published in Circulation • Feb 22, 2005

Authors:

Alan H. Gradman

Roland E. Schmieder

R. Lins

Abstract

BACKGROUND: Stopping the detrimental effects of the renin-angiotensin system at the most upstream point of the cascade offers theoretical advantages for cardiovascular protection. This study compares the antihypertensive efficacy and safety of the novel oral renin inhibitor aliskiren with placebo an...

Subject

Aliskiren

Medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!